Lucid Diagnostics prices $25M public offering of 25M shares at $1.00 per share

Lucid Diagnostics Inc.

Priced 25,000,000 shares of common stock at $1.00 per share; gross proceeds ~$25M before expenses.
Underwriters granted 30-day option to purchase up to additional 3,750,000 shares at the same price.
Net proceeds to be used for working capital and general corporate purposes; closing expected Sept 11, 2025.
Canaccord Genuity and BTIG are joint bookrunners; Maxim Group is co-manager.
Offering made under effective shelf registration statement S-3 (No. 333-268560).

item 1.01item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.